Vaxcyte

Vaxcyte's Halloween 2024 Celebration was a treat! Our colleagues outdid themselves once again with this year’s costumes, serving up some seriously creative looks. Check out members of our Protein group below! #TeamCulture #Halloween

We're thrilled to share that Vaxcyte has been recognized by Great Place to Work in five categories, honoring our vibrant and values-driven culture: • #𝟰 Best National Workplaces in BioPharma • #𝟭𝟭 Best Small & Medium Workplaces in the Bay Area • #𝟮𝟵 Best National Small & Medium Workplaces for Women • #𝟱𝟬 Best National Medium Workplaces • #𝟳𝟱 Best National Workplaces for Millennials The passion, dedication and collaboration of our Vaxcyte colleagues made this possible, and we thank you all for your many contributions that propel us to deliver on our mission to protect humankind. Check out our Great Place to Work page here: https://lnkd.in/gxPHBaSb. Join us on our mission - explore our career opportunities: https://lnkd.in/g54g7pNx #GreatPlacetoWork #culture #biotech

We're thrilled to announce that our President and CFO, Andrew Guggenhime, has been named a Bay Area CFO of the Year! Andrew's exceptional leadership and financial expertise have been crucial in advancing our mission to protect humankind from the consequences of bacterial infections, and this well-deserved honor recognizes his significant contributions to both Vaxcyte and the broader biotech industry. Congratulations, Andrew! Your dedication to our Company and our mission is truly inspiring. Read more about Andrew here: https://lnkd.in/dJ_Hfmu2 #BayAreaCFOOfTheYearAwards #CFOVisionaries2024 #SupportLarkinStreet

Behind our innovative technology is a team of passionate individuals collaborating to re-engineer high-fidelity vaccines at scale. All of our employees play a part in realizing our goal of developing vaccines that prevent or treat some of the most invasive bacterial diseases in circulation today. Hear more from Vaxcyte’s leaders about how our team is going beyond to protect humankind. #vaccineinnovation #biotech #culture

Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs.   We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team.   For more, read the full press release here: https://lnkd.in/g72D5AUd  #Vaccines #Biotechnology #ProtectHumankind #PCV

Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs.   We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team.   For more, read the full press release here: https://lnkd.in/g72D5AUd  #Vaccines #Biotechnology #ProtectHumankind #PCV

We are proud to share that Andrew Guggenhime, our President and CFO, has been named a finalist for the Bay Area CFO of the Year Awards presented by the San Francisco Business Times in partnership with Larkin Street Youth Services. This recognition is a testament to Andrew’s exceptional leadership, strategic vision and his unwavering dedication to delivering on our mission to protect humankind from the consequences of bacterial diseases. It’s also a reflection of the incredible work of our entire team, whose passion and commitment drive our shared success. Head here to learn more about the awards, the finalists and Larkin Street Youth Services, a leading Bay Area nonprofit empowering homeless and at-risk youth: https://lnkd.in/gbPEAG2G #BayAreaCFOAwards

As the summer comes to a close, we want to give a huge thanks to all of our 2024 summer interns for their hard work, dedication and enthusiasm these past few months! Our interns have been working at our San Carlos headquarters across various departments including finance, facilities, protein development, supply chain, CMC and immunoassay. We’re passionate about developing the next generation of biotech leaders and giving students an opportunity to gain valuable hands-on work experience to complement their college curriculum. #biotech #interns [From left to right: Avery Tuthill, Rachna Balasubramanian Maya Narang Vijini Liyanage, Surabhi Pandey and Donovan Pareja-jimenez (not pictured: Katherine Brenner).]

We are pleased to share that the VAX-24 Phase 2 study in adults aged 65 and older has been published in the medical journal Vaccine. The publication of these positive results is a testament to the potential of VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV), as well as our cell-free technology in developing carrier-sparing vaccines. Our PCV candidates, VAX-24 and VAX-31, our 31-valent PCV, are designed to deliver the broadest-spectrum of coverage to protect against invasive pneumococcal disease (IPD) in adults and infants while maintaining coverage of the historically circulating strains. Congratulations to the authors of this important publication. https://lnkd.in/dzNssgYU

Pipetting - the Olympic sport you’ve never heard of. In honor of the Summer Olympics, we recently hosted our first-ever Pipette Olympics during which our talented team members competed in three group-based events — the pipette tip toss, pipette painting and pipette relay. The competition was fierce, leading to a speed pipetting tiebreaker. Congratulations to our gold medalist, early-stage Analytical Development/Conjugation team, who took pipetting to a whole new level! Shoutout to our silver and bronze medalists on the Analytical and Drug Product teams. Thank you to everyone who participated and made this event unforgettable! #culture #team #pipette #olympics #summerolympics